Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease
Author(s)
Batzloff, Michael R.
Pandey, Manisha
Olive, Colleen
Good, Michael F.
Year published
2006
Metadata
Show full item recordAbstract
Rheumatic fever (RF) and rheumatic heart disease (RHD) are post-infectious complications of an infection (or repeated infection) with the Gram-positive bacterium Streptococcus pyogenes (also known as group A streptococcus, GAS). RF and RHD are global problems and affect many indigenous populations of developed countries and many developing countries. However, RF and RHD are only part of a larger spectrum of diseases caused by this organism. The development of a vaccine against GAS has primarily targeted the abundant cell-surface protein called the M-protein. This review focuses on different M-protein-based-subunit vaccine ...
View more >Rheumatic fever (RF) and rheumatic heart disease (RHD) are post-infectious complications of an infection (or repeated infection) with the Gram-positive bacterium Streptococcus pyogenes (also known as group A streptococcus, GAS). RF and RHD are global problems and affect many indigenous populations of developed countries and many developing countries. However, RF and RHD are only part of a larger spectrum of diseases caused by this organism. The development of a vaccine against GAS has primarily targeted the abundant cell-surface protein called the M-protein. This review focuses on different M-protein-based-subunit vaccine approaches and the different delivery technologies used to administer these vaccine candidates in preclinical studies.
View less >
View more >Rheumatic fever (RF) and rheumatic heart disease (RHD) are post-infectious complications of an infection (or repeated infection) with the Gram-positive bacterium Streptococcus pyogenes (also known as group A streptococcus, GAS). RF and RHD are global problems and affect many indigenous populations of developed countries and many developing countries. However, RF and RHD are only part of a larger spectrum of diseases caused by this organism. The development of a vaccine against GAS has primarily targeted the abundant cell-surface protein called the M-protein. This review focuses on different M-protein-based-subunit vaccine approaches and the different delivery technologies used to administer these vaccine candidates in preclinical studies.
View less >
Journal Title
Immunologic Research
Volume
35
Issue
3
Subject
Immunology
Immunology not elsewhere classified